Skip to content

Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis: A Multiple Centers, Randomized, Assessor- and Participant-blind, Controlled, Cross-over Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02432508
Enrollment
200
Registered
2015-05-04
Start date
2014-10-31
Completion date
2016-12-31
Last updated
2015-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Chronic, Pruritus

Keywords

acupuncture, laser, uremic pruritus, randomized clinical trial

Brief summary

Uremic pruritus is a clinically significant symptom which imposes heavy impact on the quality of life of patients with chronic kidney disease undergoing hemodialysis. In order to investigate the clinical efficacy and mechanism, the investigators designed a multiple centers, randomized, assessor- and participant-blind, controlled, cross-over clinical trial. This trial will be conducted at Taichung branch, Feng-yuan branch and the Eastern branch of CMUH.

Detailed description

We plan to enroll 200 volunteer patients with uremic pruritus. After the waiting period (as the waiting list group), you will be randomized to laser acupuncture and sham laser acupuncture group. Each group will include 100 patients and given intervention according to their hemodialysis frequency, i.e., BIW or TIW. The intervention will then be crossed over to the other one after 4 week of wash-our period. Outcome measurement includes questionnaires, biochemistry analysis, instrumental analysis and medication score.

Interventions

DEVICELaser acupuncture (Olympic)

Physiolaser Olympic laser acupuncture device (50mW, 655nm)

DEVICESham Laser acupuncture (Olympic)

Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age\>20y/o, ESRD patient, pruritus symptoms persist longer than 4 weeks

Exclusion criteria

* immunosupression agents use, undergo chemotherapy * drug abuser * pregnancy women * patient with psychiological disorder * arrhythemia, pacemaker device use * local skin infection over laser acupuncture site * patient allergy to laser acupuncture treament

Design outcomes

Primary

MeasureTime frameDescription
Pruritus Visual Analogue Scale20 weeksWe plan to enroll 200 volunteer patients with uremic pruritus. After the waiting period (4weeks), the patients will be randomized to laser acupuncture and sham laser acupuncture group (4weeks). Each group will include 100 patients and given intervention according to their hemodialysis frequency, i.e., BIW or TIW. The intervention will then be crossed over to the other one after 4 week of wash-our period. Outcome measurement includes questionnaires, biochemistry analysis, instrumental analysis and medication score will perform in the last 4 weeks. Pruritus Visual Aaalogue Scale questionnaire will perform on each visit of hemodialysis.

Secondary

MeasureTime frameDescription
Short-Form-36 Health Survey (SF-36)20 weeksSF-36 questionnaire will perform in the begin, 4th, 8th, 12th, 16th and 20th week.
Dermatology Life Quality Index (DLQI)20 weeksDLQI questionnaire will perform in the begin, 4th, 8th, 12th, 16th and 20th week.
The 5-D itch scale20 weeksThe 5-D itch scale will perform in the begin, 4th, 8th, 12th, 16th and 20th week.
The Pittsburgh Sleep Quality Index; PSQI20 weeksPSQI will perform in the begin, 4th, 8th, 12th, 16th and 20th week.
Beck Depression Inventory, BDI20 weeksBDI will perform in the begin, 4th, 8th, 12th, 16th and 20th week.

Countries

Taiwan

Contacts

Primary ContactChang Chiz-Tzung, Ph.D.
D19863@mail.cmuh.org.tw886 0422052121
Backup ContactChen Hung-Chih, M.D.
D18797@mail.cmuh.org.tw886 0422052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026